Inhibiting the TGF-β signalling pathway as a means of cancer immunotherapy

Bibliography

• DEBBAS M, WHITE E: Wild-type p53 mediates apoptosis by ElA, which is inhibited by ElB. Genes Dev. (1993) 7:546–554.
   PubMed Web of Science ®Google Scholar
• ASSOIAN RK, KOMORIYA A, MEYERS CA, MILLER DM, SPORN MB: Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. " Biol. Chem. (1983) 258:7155–7160.
   Google Scholar
• FROLIK CA, DART LL, MEYERS CA, SMITH DM, SPORN MB: Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc. Natl. Acad. Sci. USA (1983) 80:3676–3680.
   PubMed Web of Science ®Google Scholar
• CHOUAIB S, ASSELIN-PATUREL C, MAMI-CHOUAIB F, CAIGNARD A, BLAY JY: The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today (1997) 18:493–497.
   PubMedGoogle Scholar
• BECK C, SCHREIBER H, ROWLEY D:Role of TGF-beta in immune-evasion of cancer. Microsc. Res. Tech. (2001) 2:387–395.
   Google Scholar
• DE VISSER KE, KAST WM: Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia (1999) 13:1188–1199.
   PubMed Web of Science ®Google Scholar
• SHAH AH, LEE C: TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. Prostate (2000) 45:167–172.
   PubMed Web of Science ®Google Scholar
• VON BERNSTORFF W, VOSS M, FREICHEL S et al: Systemic and local immunosuppression in pancreatic cancerpatients. Clin. Cancer Res. (2001) 7:925s–932s.
   Google Scholar
• MIESCHER S, WHITESIDE TL, MORETTA L, VON FLIEDNER V: Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.j Immunol (1987) 138:4004–4011.
   PubMed Web of Science ®Google Scholar
• MOHAGHEGHPOUR N, PARHAMI B, DOWLATSHAHI K, KADJEHNOURI D, ELDER JH, CHISARI FV: Immunoregulatory properties of human esophageal tumor extract. Immunol (1979) 122:1350–1358.
   Web of Science ®Google Scholar
• BODMER S, STROMMER K, FREI K et al.: Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. Immunol (1989) 143:3222–3229.
   Google Scholar
• D'ANDREA A, ASTE-AMEZAGA M, VALIANTE NM, MAX, KUBIN M,TRINCHIERI G: Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. Exp. Med. (1993) 178:1041–1048.
   PubMed Web of Science ®Google Scholar
• BALCH CM, DOUGHERTY PA, TILDEN AB: Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann. Surg. (1982) 196:645–650.
   PubMed Web of Science ®Google Scholar
• HERSEY P: Impediments to successful immunotherapy. Phannacol The]: (1999) 81:111–119.
   Web of Science ®Google Scholar
• NAKAMURA M, KATANO M, KUWAHARA A et al.: Transforming growth factor beta1 (TGF-betal) is a preoperative prognostic indicator in advanced gastric carcinoma. Br. J Cancer (1998) 78:1373–1378.
   PubMed Web of Science ®Google Scholar
• LEACH DR, KRUMMEL ME ALLISON JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science(1996) 271: 1734-1736.
   Google Scholar
• MURRAY PA, BARRETT-LEE P, TRAVERS M, LUQMANI Y, POWLES T, COOMBES RC: The prognostic significance of transforming growth factors in human breast cancer. Br.j Cancer (1993) 67:1408–1412.
   PubMed Web of Science ®Google Scholar
• KONG FM, ANSCHER MS, MURASE T, ABBOTT BD, IGLEHART JD,\JIRTLE RL: Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. (1995) 222:155–162.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN E, GOLD LI, KLIMSTRA D, ZENG ZS, WINAWER S, COHEN A: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidennol Biomarkers Prey (1995) 4:549–554.
   PubMed Web of Science ®Google Scholar
• SAITO H, TSUJITANI S, OKA S et al.: The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer (1999) 86:1455–1462.
   PubMed Web of Science ®Google Scholar
• YOUNG MR, WRIGHT MA, LOZANO Y, MATTHEWS JP, BENEFIELD J, PRECHEL MM: Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer (1996) 67:333–338.
   PubMed Web of Science ®Google Scholar
• KONG FM, WASHINGTON MK, JIRTLE RL, ANSCHER MS: Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer (1996) 16:47–59.
   PubMed Web of Science ®Google Scholar
• BELLONE G, TURLETTI A, ARTUSIO E et al: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. .1 Pathol (1999) 155:537–547.
   Google Scholar
• WIKSTROM P, STATTIN P, FRANCK-LISSBRANT I, DAMBER JE, BERGH A: Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate (1998) 37:19–29.
   PubMed Web of Science ®Google Scholar
• MIYAZONO K, KUSANAGI K, INOUE H: Divergence and convergence of TGF-beta/BMP signaling. j Cell Physiol (2001) 187:265–276.
   PubMed Web of Science ®Google Scholar
• MASSAGUE J: The transforming growthfactor-beta family. Annu. Rev Cell Biol. (1990) 6:597–641.
   PubMedGoogle Scholar
• DABOVIC B, CHEN Y, COLAROSSI C et al.: Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF- [beta] bioavailability. .1 Cell Biol. (2002) 156:227–232.
   Google Scholar
• STERNER-KOCK A, THOREY IS, KOLI K et al.: Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev. (2002) 16:2264–2273.
   PubMed Web of Science ®Google Scholar
• KAARTINEN V, VONCKEN JW, SHULER C et al.: Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat. Genet. (1995) 11:415–421.
   PubMed Web of Science ®Google Scholar
• SANFORD LP, ORMSBY I,GITTENBERGER-DE GROOT AC et al: TGEbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGEbeta knockout phenotypes. Development (1997) 124:2659–2670.
   PubMed Web of Science ®Google Scholar
• DUNKER N, KRIEGLSTEIN K: Targetedmutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur. .1 Biochem. (2000) 267:6982–6988.
   PubMedGoogle Scholar
• MASSAGUE J: TGF-beta signal transduction. Annu. Rev. Biochem. (1998) 67:753–791.
   PubMed Web of Science ®Google Scholar
• BLOBE GC, SCHIEMANN WP, PEPIN MC et al.: Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. Biol. Chem. (2001) 276:24627–24637.
   Web of Science ®Google Scholar
• SANKAR S, MAHOOTI-BROOKS N, CENTRELLA M, MCCARTHY TL, MADRI JA: Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2.1 Biol. Chem. (1995) 270:13567–13572.
   PubMed Web of Science ®Google Scholar
• BROWN CB, BOYER AS, RUNYAN RB, BARNETT JV: Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science (1999) 283:2080–2082.
   PubMed Web of Science ®Google Scholar
• DENG X, BELLIS S, YAN Z, FRIEDMAN E: Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta], in cells with nonfunctional TGF-beta receptor type III. Cell Growth Differ. (1999) 10:11–18.
   PubMedGoogle Scholar
• LEWIS KA, GRAY PC, BLOUNT AL et al.: Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature (2000) 404:411–414.
   PubMed Web of Science ®Google Scholar
• LOPEZ-CASILLAS F, PAYNE HM, ANDRES JL, MASSAGUE J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. .1 Cell Biol. (1994) 124:557–568.
   Google Scholar
• BLOBE GC, LIU X, FANG SJ, HOW T, LODISH HF: A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC.J. Biol. Chem. (2001) 276:39608–39617.
   Google Scholar
• EICKELBERG 0, CENTRELLA M, REISS M, KASHGARIAN M, WELLS RG: Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. .1 Biol. Chem. (2002) 277:823–829.
   Google Scholar
• YU L, HEBERT MC, ZHANG YE: TGF-beta receptor-activated p38 MAP kinase mediates Smad-independentTGF-beta responses. EMBO J. (2002) 21:3749–3759.
   PubMed Web of Science ®Google Scholar
• LARSSON J, GOUMANS MJ, SJOSTRAND LJ et al.: Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J. (2001) 20:1663–1673.
   PubMed Web of Science ®Google Scholar
• BLOBE GC, SCHIEMANN WP, LODISH HF: Role of transforming growth factor beta in human disease. N Engl. J. Med. (2000) 342:1350–1358.
   PubMed Web of Science ®Google Scholar
• RAVITZ MJ, WENNER CE: Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv. Cancer Res. (1997) 71:165–207.
   PubMed Web of Science ®Google Scholar
• MAEHARA Y, KAKEJI Y, KABASHIMA Aet al.: Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J. Clio. Oncol (1999) 17:607–614.
   Google Scholar
• PEPPER MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev (1997) 8:21–43.
   PubMedGoogle Scholar
• DICKSON MC, MARTIN JS, COUSINS FM, KULKARNI AB, KARLSSON S, AKHURST RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development (1995) 121: 1845-1854.
   Google Scholar
• OSHIMA M, OSHIMA H,TAKETO MM: TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. (1996) 179:297–302.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA A, GARCIA C, PAULES AB et al.: Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene (1998) 17:1969–1978.
   PubMed Web of Science ®Google Scholar
• GRADY WM, MYEROFF LL, SWINLER SE et al.: Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. (1999) 59:320–324.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ S, WANG J, MYEROFF L et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 268:1336–1338.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of a tumoursuppressor role for members of the TGF-I3 signalling pathway.
   Google Scholar
• PICON A, GOLD LI, WANG J,COHEN A, FRIEDMAN E: A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta 1. Cancer Epidemiol Biomarkers Prey. (1998) 7:497–504.
   PubMed Web of Science ®Google Scholar
• BRANDES ME, WAKEFIELD LM, WAHL SM: Modulation of monocyte typeI transforming growth factor-beta receptorsby inflammatory stimuli. J. Biol. Chem.(1991) 266:19697–19703.
   PubMed Web of Science ®Google Scholar
• LETTERIO JJ, ROBERTS AB: Regulation of immune responses by TGF-beta. Anna. Rev Immunol (1998) 16:137–161.
   PubMed Web of Science ®Google Scholar
• KEHRL JH, WAKEFIELD LM, ROBERTS AB et al.: Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. (1986) 163:1037–1050.
   PubMed Web of Science ®Google Scholar
• GORELIK L, FLAVELL RA: Transforming growth factor-beta in T-cell biology. Nat. Rev Immunol (2002) 2:46–53.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, KITANI A,STROBER W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. (2001) 194:629–644.
   PubMed Web of Science ®Google Scholar
• SHULL MM, ORMSBY I, KIER AB et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 359:693–699.
   PubMed Web of Science ®Google Scholar
• NAKAO A, MIIKE S, HATANO M et al.: Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. Exp. Med. (2000) 192:151–158.
   PubMed Web of Science ®Google Scholar
• LUCAS PJ, KIM SJ, MELBY SJ, GRESS RE: Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J. Exp. Med. (2000) 191:1187–1196.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the important role of the TGF-I3 signalling pathway on T cell homeostasis.
   Google Scholar
• GORELIK L, FLAVELL RA: Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 12:171-181. Demonstrates the important role of the TGF-I3 signalling pathway on T cell homeostasis.
   Google Scholar
• BOGDAN C, PAIK J, VODOVOTZ Y, NATHAN C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10../. Biol. Chem. (1992) 267:23301–23308.
   PubMed Web of Science ®Google Scholar
• RIEDL E, STROBL H, MAJDIC 0, KNAPP W: TGF-beta 1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. Immunol (1997) 158:1591–1597.
   Web of Science ®Google Scholar
• GEISSMANN F, REVY P, REGNAULT A et al.: TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol (1999) 162:4567–4575.
   PubMed Web of Science ®Google Scholar
• TU H, JACOBS SC, BORKOWSKI A, KYPRIANOU N: Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-betal and bc1-2 expression. Int. J. Cancer (1996) 69:357–363.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G,BEAUCHAMP RD, KOEPPEN H et al.: A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 rDNA escapes immune surveillance. Proc. Nati Acad. Sci. USA (1990) 87:1486–1490.
   Google Scholar
• •First demonstration of a role for TGF-I3 in cancer-mediated irnmunosuppression.
   Google Scholar
• ARTEAGA CL, CARTY-DUGGER T, MOSES HL, HURD SD,PIETENPOL JA: Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. (1993) 4:193–201.
   PubMedGoogle Scholar
• WIESER R, ATTISANO L, WRANA JL,MASSAGUE J: Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Ma Cell Biol. (1993) 13:7239–7247.
   Web of Science ®Google Scholar
• MAEDA H, SHIRAISHI A: TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice.Immunol (1996) 156:73–78.
   Web of Science ®Google Scholar
• ARTEAGA CL, HURD SD, WINNIER AR, JOHNSON MD, FENDLY BM, FORBES JT: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer
   Google Scholar
• ••progression. J. Clin. Invest. (1993) 92:2569–2576.
   Google Scholar
• WOJTOWICZ-PRAGA S, VERMA UN, WAKEFIELD L et al: Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. Immunothec Emphasis Tumor Immunol (1996) 19:169–175.
   PubMed Web of Science ®Google Scholar
• MATTHEWS E, YANG T, JANULIS L et al.: Down-regulation of TGF-betal production restores immunogenicity in prostate cancer cells. ELI Cancer (2000) 83:519–525.
   Web of Science ®Google Scholar
• WON J, KIM H, PARK EJ, HONG Y, KIM SJ, YUN Y: Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res. (1999) 59:1273–1277.
   PubMed Web of Science ®Google Scholar
• GORELIK L, FLAVELL RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. (2001) 7:1118–1122.
   PubMed Web of Science ®Google Scholar
• ••Excellent demonstration that blockade ofTGF-I3 in T cells can enhance immunosurveillance in vivo.
   Google Scholar
• WU SP, SUN LZ, WILLSON JK, HUMPHREY L, KERBEL R, BRATTAIN MG: Repression of auticrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ. (1993) 4:115–123.
   PubMedGoogle Scholar
• BOSHER JM, LABOUESSE M: RNA interference: genetic wand and genetic watchdog. Nat. Cell Biol. (2000) 2:E31–E36.
   PubMed Web of Science ®Google Scholar
• INMAN GJ, NICOLAS FJ, CALLAHAN JF et al: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol (2002) 62:65–74.
   PubMed Web of Science ®Google Scholar
• YANG YA, DUKHANINA 0, TANG B et al.: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.Clin. Invest. (2002) 109:1607–1615.
   Google Scholar
• •Excellent demonstration that lifelong blockade of TGF-I3 signalling does not produce obvious adverse side effects.
   Google Scholar
• BANDYOPADHYAY A, ZHU Y, MALIK SN et al.: Extracellular domain of TGEbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene (2002) 21:3541-3551.ao.HUBER D, PHILIPP J, FONTANA A:Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. Immunol (1992) 148:277–284.
   Google Scholar